Contraceptive needs of the perimenopausal woman

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 3, 2002, Pages 575-588

  Williams, J Kell ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; ETONOGESTREL; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

AGING; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR RISK; CONTRACEPTION; DRUG EFFICACY; ENDOMETRIOSIS; FEMALE; FEMALE STERILIZATION; FERTILITY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MATERNAL AGE; MENOPAUSE; OSTEOPOROSIS; OVARY CANCER; OVARY FUNCTION; PATIENT COMPLIANCE; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

CLIMACTERIC; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTRAUTERINE DEVICES; MEDROXYPROGESTERONE 17-ACETATE; PREGNANCY; RISK ASSESSMENT; STERILIZATION, REPRODUCTIVE;

EID: 0036739899     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(02)00017-7     Document Type: Review

References (90)

1. Toner JP, Flood JT. Fertility after the age of 40. Obstet Gynecol Clin North Am 1993;20:261-72.
2. Klein J, Sauer M. Assessing fertility in women of advanced reproductive age. Am J Obstet Gynecol 2001;185:758-70.
3. Kidd SA, Eskenazi B, Wyrobek AJ. Effects of male age on semen quality and fertility: a review of the literature. Fertil Steril 2001;75:237-48.
4. Schmidt-Sarosi C. Infertility in the older woman. Clin Obstet Gynecol 1998;41:940-50.
5. Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998;30:24-9.
6. Centers for Disease Control and Prevention. Safe motherhood: preventing pregnancy-related illness and death. Available at: www.cdc.gov/nccdphp/drh. Accessed July 22, 2002.
7. Maternal mortality-United States, 1982-1996. MMWR Morb Mortal Wkly Rep 1998;47:705-7.
8. State-specific maternal mortality among black and white women. MMWR Morb Mortal Wkly Rep 1999;48:492-6.
9. Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1161-70.
10. Trussell J, Leveque JA, Koenig JD, et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health 1995;85:494-503.
11. Peterson HB, Jeng G, Folger SG, et al. The risk of menstrual abnormalities after tubal sterilization: findings from the US Collaborative Review of Sterilization. N Engl J Med 2000;343: 1681-7.
12. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal sterilization, hysterectomy, and the risk of ovarian cancer: a prospective study. JAMA 1993;270:2813-9.
13. Hillis SD, Marchbanks PA, Tylor LR, Peterson HB. Poststerilization regret: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 1999;93:889-95.
14. Nachtigall LE. The symptoms of perimenopause. Clin Obstet Gynecol 1998;41:921-7.
15. Sivin I, Stern J, Coutinho E. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day and the copper T380A IUDs. Contraception 1991;44: 473-80.
16. Onyeka BA. Levonorgestrel-releasing (20 mcg/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. Br J Obstet Gynaecol 2001;108:770-1.
17. Berenson AB, Radecki CM, Grady JJ, et al. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001;98:576-82.
18. Ott SM, Scholes D, LaCroix AZ, et al. Effects of contraceptive use on bone biochemical markers in women. J Clin Endocrinol Metab 2001;86:179-85.
19. Kaunitz AM. Lunelle monthly injectable contraception: an effective, safe, and convenient new birth control option. Arch Gynecol Obstet 2001;265:119-23.
20. Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ 1970;2: 203-9.
21. Farley TM, Collins J, Schlesselmann JJ. Hormonal contraception and the risk of cardiovascular disease: an international perspective. Contraception 1998;57:211-30.
22. WHO Scientific Group. Cardiovascular disease and steroid contraception: report of a WHO scientific group. Technical Report 877. Geneva: World Health Organization; 1998.
23. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001;161:1065-70.
24. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, Cates W Jr, Stewart GK, Guest F, et al, editors. Contraceptive technology. 17th edition. New York: Ardent Media Inc.; 1998. p. 779-844.
25. Ortho-McNeil P. Ortho annual birth control study 1999. Raritan, NJ: Ortho-McNeil Pharmaceutical; 2000.
26. Davis A, Wysocki S. Clinician/patient interaction: communicating the benefits and risks of oral contraceptives. Contraception 1999;59:39S-42S.
27. Sulak PJ. Oral contraceptives: therapeutic uses and quality-of-life benefits. Contraception 1999; 59:35S-8S.
28. Sulak PJ. The perimenopause: a critical time in a women's life. Int J Fertil 1996;41:85-9.
29. Croft P, Hanniford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989;298:165-8.
30. Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results from the transnational study on oral contraceptives and the health of young women. Contraception 1997;56:129-40.
31. Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose contraceptives. N Engl J Med 1996;335:8-15.
32. Sidney S, Petitti DB, Quesenberry CP. Myocardial infarction in user of low-dose oral contraceptives. Obstet Gynecol 1996;88:939-44.
33. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
34. Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women's perspective. Eur J Contracept Reprod Health Care 1996;1:275-84.
35. Peipert JF, Gutmann J. Oral contraceptive risk assessment: a survey of 247 educated women. Obstet Gynecol 1993;82:112-7.
36. Bracher M, Santow G. Premature discontinuation of contraception in Australia. Fam Plann Perspect 1992;24:58-65.
37. Serfaty D. Medical aspects of oral contraceptive discontinuation. Adv Contracept 1992;8:21-33.
38. Rosenberg MJ, Waugh MS, Bumhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89-92.
39. La Vecchia C, Tavani A, Franceschi S, Parazzini F. Oral contraceptives and cancer: a review of the evidence. Drug Saf 1996;14:260-72.
40. Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-5.
41. Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 1989;40:1-38.
42. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992;80:708-14.
43. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 1995;85:793-801.
44. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994;83:419-24.
45. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139:654-61.
46. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339:424-8.
47. Villard-Mackintosh L, Vessey MP, Jones L. The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. Br J Obstet Gynaecol 1989;96:783-8.
48. Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987;257:796-800.
49. Rubin GL, Wingo PA, Layde PM, et al. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 1983; 249:1600-4.
50. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception 1991; 43:557-79.
51. Jick SS, Walker AM, Jick H. Oral contraceptives and endometrial cancer. Obstet Gynecol 1993; 82:931-5.
52. Fernandez E, La Vecchia C, Franceschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998;9:295-300.
53. Martinez ME, Grodstein F, Giovannucci E, et al. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:1-5.
54. Potter JD, McMichael AJ. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst 1983;71:703-9.
55. Troisi R, Schairer C, Chow WH, et al. Reproductive factors, oral contraceptive use, and risk of colorectal cancer. Epidemiology 1997;8:75-9.
56. Fernandez E, LaVecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer 2001;84:72-727.
57. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CWJ. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517-23.
58. Potter JD. Hormones and colon cancer. J Natl Cancer Inst 1995;87:1039-40.
59. Bennion LJ, Ginsberg RL, Gernick MB, Bennett PH. Effects of oral contraceptives on the gallbladder bile of normal women. N Engl J Med 1976;294:189-92.
60. Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992;12:1327-30.
61. Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982;144:630-5.
62. Boston Collaborative Drug Surveillance Program. Functional ovarian cysts and oral contraceptives. JAMA 1974;228:68-9.
63. Vessey M, Metcalfe A, Wells C, et al. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. BMJ 1987;294:1518-20.
64. Caillouette JC, Koehler AL. Phasic contraceptive pills and functional ovarian cysts. Am J Obstet Gynecol 1987;156:1538-42.
65. Grimes DA, Godwin AJ, Rubin A, et al. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994;83:29-34.
66. Lanes SF, Birmann B, Walker AM, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol 1992;166:956-61.
67. Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ 1986;293:359-62.
68. Parazzini F, Negri E, La Vecchia C, et al. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992;79:430-3.
69. Chiaffarino F, Parazzini F, La Vecchia C, et al. Oral contraceptive use and benign gynecologic conditions: a review. Contraception 1998;57:11-8.
70. Brinton LA, Vessey MP, Flavel R, Yeates D. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-14.
71. Royal College of General Practitioners' Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet 1977; 1:624.
72. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
73. Kleerekoper M, Brienza RS, Schultz LR, Johnson CC. Oral contraceptive use may protect against low bone mass. Arch Intern Med 1991;151:1971-6.
74. Kritz-Silverstein D, Barrett-Connor E. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health 1993;83:100-2.
75. Gambacciani M, Spinetti A, Taponeco F, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol 1994;83:392-6.
76. Michaelsson K, Baron JA, Farahmand BY, et al. Oral-contraceptive use and the risk of hip fracture: a case-control study. Lancet 1999;353:1481-4.
77. Casper RF, Dodin S, Reid RL. The effect of 20mcg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause 1997;4:139-47.
78. Shargil AA. Hormone replacement therapy in perimenopausal women with a low dose oral contraceptive preparation. Int J Fertil 1985;30:15-28.
79. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol 1990;43:1221-30.
80. Jorgensen C, Picot MC, Bologna C, Sany J. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis 1996;55:94-8.
81. Giannotti B, Carli P. Hormonal contraception and the skin. Eur J Contracept Reprod Health Care 1998;3:17-9.
82. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-54.
83. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-22.
84. Akerlund M. Pathophysiology of dysmenorrhea. Acta Obstet Gynecol Scand 1979;87:27-32.
85. Apgar BS. Dysmenorrhea and dysfunctional uterine bleeding. Prim Care 1997;24:161-78.
86. Larsson G, Milsom I, Lindstedt G, Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992;46:327-34.
87. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001;98:771-8.
88. den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999;59:357-62.
89. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.
90. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring (NuvaRing) for ovulation inhibition. Fertil Steril 2001;75:865-70.